KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $24.2 million.

  • TherapeuticsMD's Non-Current Assets fell 1178.92% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.5 million, marking a year-over-year decrease of 1382.33%. This contributed to the annual value of $26.6 million for FY2024, which is 1570.78% down from last year.
  • Per TherapeuticsMD's latest filing, its Non-Current Assets stood at $24.2 million for Q3 2025, which was down 1178.92% from $25.0 million recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Non-Current Assets ranged from a high of $52.3 million in Q1 2021 and a low of $24.2 million during Q3 2025
  • Over the past 5 years, TherapeuticsMD's median Non-Current Assets value was $34.1 million (recorded in 2023), while the average stood at $37.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 601.81% in 2021, then tumbled by 2979.16% in 2022.
  • Quarter analysis of 5 years shows TherapeuticsMD's Non-Current Assets stood at $50.0 million in 2021, then fell by 29.79% to $35.1 million in 2022, then fell by 10.24% to $31.5 million in 2023, then fell by 15.71% to $26.6 million in 2024, then decreased by 9.02% to $24.2 million in 2025.
  • Its Non-Current Assets stands at $24.2 million for Q3 2025, versus $25.0 million for Q2 2025 and $25.7 million for Q1 2025.